AU
UK
CA
NZ
IND
US
Strategic Partnership in Ophthalmology Devices and Group Purchasing Organizations (GPOs)Iridex Corporation, a provider of laser-based medical systems for ophthalmology, has entered into a partnership with EyeProGPO, a U.S.-focused group purchasing organization serving more than 1,800 ophthalmology practices, ambulatory surgery centers, and hospitals. The agreement …
AtaiBeckley Inc. has reported Phase 2a clinical data for BPL-003, an intranasal psychedelic-based therapy targeting treatment-resistant depression (TRD), highlighting both rapid onset and sustained efficacy. The findings arrive as investor and industry attention toward next-generation mental health treatments continues to expand, particularly in segments …
FDA Orphan Drug Designation Expands Scope in Pediatric Brain Cancer TreatmentPlus Therapeutics has secured U.S. FDA Orphan Drug Designation for REYOBIQ, its investigational radiotherapeutic targeting pediatric malignant gliomas. Notably, the designation extends beyond the company’s initial request to include pediatric ependymoma, broadening the potential …
iBio IBIO-600 Phase 1 Trial Marks Transition to Clinical-Stage Biotech
UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …
Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …
BioXcel Therapeutics has initiated patient enrollment in a Phase 2a clinical trial evaluating BXCL501 for acute stress reactions (ASR), marking a notable step in the company’s effort to expand its neuroscience pipeline. The study, funded by the U.S. Department of War and led by …
AI Nose Healthcare Deployment Signals Strategic Expansion into High-Value InfrastructureAinos, Inc. (NASDAQ: AIMD) has announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across critical hospital environments. This move marks a notable extension of its Smell AI …
Capital Raising and Liquidity Position Strengthen Acquisition Pipeline
Please wait processing your request...